Abstract 604P
Background
Tyrosine kinase inhibitors (TKIs) are standard of care for radioiodine-refractory differentiated thyroid cancer(RAIR-DTC). Cabozantinib (Cabo) is a TKI approved for RAIR-DTC in the US (patients [pts] aged ≥12 years who progressed after VEGFR-targeted therapy) and in the EU (adult pts who progressed after systemic therapy), based on significant progression-free survival (PFS) improvement vs placebo in the phase 3 COSMIC-311 study (NCT03690388). BRAF mutations are common in thyroid cancer, but limited data are available to inform treatment in BRAF-mutated RAIR-DTC. BRAF- and MEK-directed therapies are approved in the US for pts with BRAF-mutated solid tumors, but supportive studies in DTC are lacking. In this planned exploratory analysis of COSMIC-311, we evaluated the efficacy and safety of Cabo vs placebo by BRAF status.
Methods
Pts with RAIR-DTC previously treated with 1-2 VEGFR-targeted therapies (lenvatinib or sorafenib required) were randomized to Cabo 60 mg PO QD or placebo. Primary endpoints were PFS and objective response rate (ORR), both per RECIST v1.1 by blinded independent review. For this analysis, outcomes were evaluated by BRAF status (BRAF-V600E or -wild type [wt]).
Results
Of258 randomized pts, BRAF status (V600E or wt) was determined for 101 pts: 27 were BRAF-V600E (Cabo 17, placebo 10) and 74 were BRAF-wt (Cabo 44, placebo 30). The PFS benefit of Cabo vs placebo was maintained irrespective of BRAF status (Table). Safety data by BRAF status were consistent with the overall study population. Table: 604P
BRAF-V600E | BRAF-wt | |||
Cabo (n=17) | Placebo (n=10) | Cabo (n=44) | Placebo (n=30) | |
PFS, median (95% CI), mo | 9.2 (3.6– NE) | 1.9 (1.0–NE) | 11.1 (7.4–NE) | 1.9 (1.8–3.6) |
Hazard ratio (95% CI) | 0.15 (0.04–0.59) | 0.23 (0.12–0.44) | ||
ORR, % (95% CI) | 18 (3.8–43.4) | 0 (0–30.8) | 11 (3.8–24.6) | 0 (0–11.6) |
NE, not estimable
Conclusions
In this subgroup analysis, Cabo was associated with improved PFS vs placebo irrespective of BRAF-V600E or wt status. These data, together with the manageable safety profile, support Cabo as a treatment option for RAIR-DTC after prior VEGFR-targeted therapy, including in BRAF-V600E disease.
Clinical trial identification
NCT03690388.
Editorial acknowledgement
Writing and editorial assistance was provided by Alexus Rivas-John, PharmD (Fishawack Communications Inc., part of Fishawack Health, Conshohocken, PA, USA).
Legal entity responsible for the study
Exelixis, Inc.
Funding
This study was funded by Exelixis, Inc. (Alameda, CA).
Disclosure
M.S. Brose: Financial Interests, Institutional, Research Grant: Exelixis, Bayer, Loxo/Lilly, Kinnate; Financial Interests, Personal, Advisory Role: Exelixis, Bayer, Loxo/Lilly, Kinnate. B. Keam: Financial Interests, Institutional, Research Funding: Ono, AZ, MSD; Financial Interests, Personal, Advisory Role: Handok, NeoImmuneTec, Trialinformatics, ImmuneOncia; Financial Interests, Personal, Other, Honoraria: AZ, Merck, MSD, LG Chem, Bayer, Yuhan. B. Robinson: Financial Interests, Personal, Leadership Role: Mayne Pharma; Financial Interests, Personal, Stocks or ownership: Mayne Pharma; Financial Interests, Personal, Other, Honoraria: Eisai, Eli Lilly; Financial Interests, Personal, Advisory Role: Eisai, Eli Lilly; Financial Interests, Personal, Speaker’s Bureau: Eisai. S. Sherman: Financial Interests, Personal, Advisory Role: Eisai Medical Research, Eli Lily; Financial Interests, Personal, Advisory Board, Co-chair: MD Anderson Cancer Center Data Safety Monitoring Board. J.A. Krajewska: Financial Interests, Personal, Advisory Role: Exelixis, Ipsen, Loxo, Lilly; Financial Interests, Personal, Other, Honoraria: Exelixis, Lilly; Financial Interests, Personal, Other, Honoraria; subinvestigator in clinical trials: Sanofi-Genzyme ; Financial Interests, Personal, Other, Honoraria for lectures: Ipsen and Sanofi-Genzyme; Financial Interests, Personal, Other, Travel Accommodations/Expenses: Ipsen, Sanofi; Financial Interests, Personal, Proprietary Information, EPO 21460001.7-1111: Patent aplications; Financial Interests, Personal, Advisory Board: Exelixis, Ipsen, Lilly, Loxo. C. Lin: Financial Interests, Personal, Advisory Role: AbbVie, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Merck KGaA, Novartis, PharmaEngine; Financial Interests, Personal, Other, Honoraria: Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Roche, Novartis; Financial Interests, Personal, Other, Travel Accommodations/Expenses: BeiGene, Daiichi Sankyo, Eli Lilly, IMPACT; Financial Interests, Personal, Advisory Board: Bayer, Novartis, Seagen. F. Vaisman: Financial Interests, Institutional, Research Funding: Eli Lilly, Exelixis; Financial Interests, Personal, Advisory Role: Eli Lilly, Ipsen; Financial Interests, Personal, Other, Honoraria: Merck, Eli Lilly, Ipsen, Sanofi; Financial Interests, Personal, Other, Travel Accommodations/Expenses: Merck, Sanofi. A.O. Hoff: Financial Interests, Personal, Full or part-time Employment, Husband: Oncologia Rede D'OR; Financial Interests, Personal, Leadership Role, Husband - President: Oncology Rede D'OR; Financial Interests, Institutional, Research Funding: Exelixis, Eli Lilly; Financial Interests, Personal, Advisory Role: Eli Lilly; Financial Interests, Personal, Other, Honoraria: Bayer; Financial Interests, Personal, Advisory Board: Eli Lilly. D.W. Bowles: Financial Interests, Institutional, Research Funding: Pfizer, Exelixis; Financial Interests, Personal, Advisory Role: Exelixis. N. Ngamphaiboon: Financial Interests, Personal, Advisory Role: MSD, Roche, Eisai, Merck, BeiGene, BMS; Financial Interests, Institutional, Research Funding: MSD, Roche, RAPT therapeutics, BeiGene, Boehringer Ingelheim Pharmaceuticals, Pfizer, Exelixis; Financial Interests, Personal, Other, Honoraria: Roche, MSD, Merck, Eisai; Financial Interests, Personal, Other, Travel Accommodations/Expenses: Roche, MSD, Eisai; Financial Interests, Personal, Advisory Board: MSD, Roche, Eisai, Merck, BeiGene, BMS, Boehringer Ingelheim. X. Guo: Financial Interests, Personal, Full or part-time Employment: Exelixis; Financial Interests, Personal, Other, Methods for selecting psoriatic arthritis subjects for treatment with a TYK2 inhibitor based on blood protein biomarker levels. (US Patent Application No. 029420.4032 - Oct 19 2021.): Patent application; Financial Interests, Personal, Stocks/Shares: Exelixis, AstraZeneca, Pfizer, AbbVie. F. Zhang, D.S. Williamson, D. Curran, N. Berry: Financial Interests, Personal, Full or part-time Employment: Exelixis, Inc.; Financial Interests, Personal, Stocks/Shares: Exelixis, Inc. M. Schwickart: Financial Interests, Personal, Full or part-time Employment: Exelixis, Inc.; Financial Interests, Personal, Stocks/Shares: Exelixis, Inc., Revolution medicine. J. Capdevila Castillon: Financial Interests, Institutional, Research Funding: Novartis, Pfizer, AstraZeneca, Advanced Accelerator Applications, Eisai, Amgen, Bayer; Financial Interests, Personal, Advisory Role: Novartis, Pfizer, Ipsen, Exelixis, Bayer, Eisai, dvanced Accelerator Applications, Amgen, Sanofi, Lilly, Huchinson Pharma, ITM, Advanz, Merck Serono, Esteve, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
250P - Impact of adjuvant chemo(radio)therapy in stage I/II testicular seminoma
Presenter: Mahmoud Eleisawy
Session: Poster Display
Resources:
Abstract
251P - LDH isozyme as a prognostic factor for patients with metastatic clear cell renal cell carcinoma (mCRCC)
Presenter: Hayato Takeda
Session: Poster Display
Resources:
Abstract
252P - Risk factors for recurrence after curative nephrectomy in non-metastatic renal cell carcinoma: A retrospective cohort study
Presenter: Kristine Tejada
Session: Poster Display
Resources:
Abstract
253TiP - WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma: A phase II multi-center study
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
254TiP - Prospective observational trial of cabozantinib plus nivolumab in Japanese patients with advanced or metastatic renal cell carcinoma: JACUMET trial
Presenter: Yuji Miura
Session: Poster Display
Resources:
Abstract
264P - Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Chia-Chi Lin
Session: Poster Display
Resources:
Abstract
266P - Clinical application and potential impact of liquid biopsy on the management of Chinese patients with metastatic castration-resistant prostate cancer (mCRPC): A territory-wide prospective analysis
Presenter: Wai Kay Philip Kwong
Session: Poster Display
Resources:
Abstract
267P - Exploring homologous recombination deficiency threshold for predicting response to PARP inhibitor in prostate cancer
Presenter: Diwei Zhao
Session: Poster Display
Resources:
Abstract
268P - Comparisons of on new-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I and DPP4I: A population-based cohort study
Presenter: Hou In Chou
Session: Poster Display
Resources:
Abstract
269P - Prostate cancer harboring low COMT expression correlates with a poor prognosis and response to enzalutamide
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract